<SEC-DOCUMENT>0001104659-20-002029.txt : 20200107
<SEC-HEADER>0001104659-20-002029.hdr.sgml : 20200107
<ACCEPTANCE-DATETIME>20200107170220
ACCESSION NUMBER:		0001104659-20-002029
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200101
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200107
DATE AS OF CHANGE:		20200107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AdaptHealth Corp.
		CENTRAL INDEX KEY:			0001725255
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				823677704
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38399
		FILM NUMBER:		20513853

	BUSINESS ADDRESS:	
		STREET 1:		220 WEST GERMANTOWN PIKE
		STREET 2:		SUITE 250
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462
		BUSINESS PHONE:		610-630-6357

	MAIL ADDRESS:	
		STREET 1:		220 WEST GERMANTOWN PIKE
		STREET 2:		SUITE 250
		CITY:			PLYMOUTH MEETING
		STATE:			PA
		ZIP:			19462

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DFB Healthcare Acquisitions Corp.
		DATE OF NAME CHANGE:	20171213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm201313-1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>



<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>AdaptHealth
Corp</B></FONT><B><FONT STYLE="font-size: 14pt">.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.75pt solid">(Exact
name of registrant as specified in its charter)&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of Earliest Event
Reported): January 1, 2020</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; width: 27%; text-align: center; padding-bottom: 2pt"><B>Delaware</B></TD>
    <TD STYLE="padding-top: 2pt; width: 2%; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; text-align: center; padding-bottom: 2pt"><B>001-38399</B></TD>
    <TD STYLE="padding-top: 2pt; width: 2%; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; border-bottom: Black 1pt solid; width: 27%; text-align: center; padding-bottom: 2pt"><B>82-3677704</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2pt; text-align: center; padding-bottom: 2pt">(State or other jurisdiction of<BR>
 incorporation)</TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; text-align: center; padding-bottom: 2pt">(Commission File Number)</TD>
    <TD STYLE="padding-top: 2pt; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt; text-align: center; padding-bottom: 2pt">(IRS Employer Identification No.)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>220 West Germantown Pike, Suite 250</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Plymouth Meeting, PA<BR>
</B>(address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>19462</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(zip code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(610) 630-6357</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>(Registrant&rsquo;s telephone number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Check the appropriate box below if the
Form 8-K is intended to</B> simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Written communication pursuant to Rule 425 under the Securities Act (17 UR 230.425)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CPR 240.14a-12)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD>Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title&nbsp;of&nbsp;each&nbsp;class</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trading&nbsp;Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name&nbsp;of&nbsp;each&nbsp;exchange&nbsp;on&nbsp;which&nbsp;registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Class A Common Stock, par value $0.0001 per share</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>AHCO</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><B>The Nasdaq Stock Market LLC</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.01 Completion of Acquisition or Disposition of Assets.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 1, 2020,
AdaptHealth LLC (&ldquo;Buyer&rdquo;), a Delaware limited liability company and wholly-owned indirect subsidiary of AdaptHealth
Corp., a Delaware corporation (the &ldquo;Company&rdquo;), completed its previously announced acquisition of NRE Holding Corporation,
a Delaware corporation (&ldquo;NRE&rdquo;) and subsidiary of McKesson Medical-Surgical, Inc., a Virginia corporation (&ldquo;Seller&rdquo;),
pursuant to the Securities Purchase Agreement, dated as of November 21, 2019 (the &ldquo;Agreement&rdquo;), by and among Buyer,
Seller, NRE and McKesson Patient Care Solutions, Inc., a Pennsylvania corporation and wholly-owned subsidiary of NRE (&ldquo;PCS&rdquo;).
On the terms and subject to the conditions set forth in the Agreement, at the closing of the Transaction (the &ldquo;Closing&rdquo;),
Buyer purchased from Seller all of the issued and outstanding equity interests of NRE (the &ldquo;Transaction&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Agreement, Buyer paid an amount in cash equal to $14 million minus certain adjustments for cash, indebtedness, transaction
expenses and net working capital (as compared to an agreed target net working capital amount) to Seller at the Closing.  In addition, Buyer may be required to make an additional payment of $1,500,000
to Seller following the Closing pursuant to the terms and conditions of a Transition Services Agreement entered into in connection
with the Closing. The total
amount of Buyer&rsquo;s investment in NRE, including restructuring costs relating to the integration of NRE&rsquo;s business into the Company&rsquo;s
platform, is expected to be approximately $30 million.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 3, 2020,
the Company issued a press release announcing the consummation of the Transaction, a copy of which is furnished as Exhibit 99.1 hereto and incorporated herein by reference. Such exhibit and the information set
forth therein shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
 &ldquo;Exchange Act&rdquo;), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated
by reference in any filing under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain statements
in this Current Report on Form 8-K may constitute &ldquo;forward-looking statements&rdquo; for purposes of the federal securities
laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team&rsquo;s expectations,
hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts
or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.
The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;expect,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;possible,&rdquo;
 &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;would&rdquo; and similar expressions
may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These forward-looking
statements are based on information available as of the date of this Current Report on Form 8-K, and current expectations, forecasts
and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not
be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking
statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events
or otherwise, except as may be required under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of a number
of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed
or implied by these forward-looking statements. A further description of such risks and uncertainties can be found in the Company&rsquo;s
filings with the Securities and Exchange Commission, including the Company&rsquo;s definitive proxy statement in connection with
the solicitation of proxies from its stockholders filed with the Securities and Exchange Commission on October 23, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 9.01. Financial Statements and Exhibits.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Financial Statements of Businesses Acquired.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">The financial statements
required by this item with respect to the Transaction will be filed as soon as practicable, and in any event not later than 71
days after the date on which this Current Report on Form 8-K is required to be filed pursuant to Item 2.01.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b) Pro Forma Financial Information.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin: 0pt 0"><FONT STYLE="font-style: normal">The pro forma financial
information required by this item with respect to the Transaction will be filed as soon as practicable, and in any event not later
than 71 days after the date on which this Current Report on Form 8-K is required to be filed pursuant to Item 2.01.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.125in; width: 8%; border: Black 1pt solid; padding-top: 12pt"><A HREF="tm201313d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
    <TD STYLE="width: 92%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt"><A HREF="tm201313d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release, dated January 3, 2020</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">AdaptHealth Corp.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">By:&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Gregg Holst</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Gregg Holst</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Dated: January 7, 2020</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm201313d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm201313d1_ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>FOR IMMEDIATE RELEASE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>ADAPTHEALTH CORP. ACQUIRES PATIENT CARE SOLUTIONS
BUSINESS</U></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>FROM MCKESSON CORPORATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>NAMES RODNEY CARSON PRESIDENT OF ADAPTHEALTH
PATIENT CARE SOLUTIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Plymouth Meeting, PA &#8211;
January 3, 2020 &#8211; AdaptHealth Corp. (NASDAQ: AHCO) (&#8220;AdaptHealth&#8221;)</B>, the third largest provider of home
medical equipment (&#8220;HME&#8221;) in the United States, announced today that it has closed the previously announced
acquisition of the Patient Care Solutions business from McKesson Corporation and named healthcare industry veteran Rodney
Carson, as President of the newly-formed AdaptHealth Patient Care Solutions (&#8220;AdaptHealth PCS&#8221;). The PCS
acquisition adds urological and ostomy products to AdaptHealth&#8217;s HME product portfolio and increases the
company&#8217;s footprint in areas such as wound care, breast pumps, incontinence supplies, and diabetic care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Carson brings nearly two decades of
healthcare operations experience to AdaptHealth PCS. He most recently served as President and CEO of CCS Medical, one of the country&#8217;s
leading providers of home medical supplies. Prior to CCS, Mr. Carson was President of Operations of MDLIVE, a national provider
of telemedicine services, as well as EVP of Operations at NationsHealth, and President of Liberty Medical Supply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;We believe that AdaptHealth PCS
is an important component of AdaptHealth&#8217;s continued expansion of its HME supply business and will allow AdaptHealth to further
enrich our product portfolio and offer our patients, healthcare professionals and commercial payor partners a truly robust suite
of products,&#8221; said Luke McGee, CEO of AdaptHealth. &#8220;Rodney is an experienced, proven and creative leader who brings
to AdaptHealth PCS a record of success in building businesses, enhancing customer experiences, and driving operational efficiencies.
He is an ideal choice to help implement our growth strategies and we are excited to welcome him to our team.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#8220;I am honored to be joining AdaptHealth
to lead the Patient Care Solutions business at this important moment in the company&#8217;s history,&#8221; said Mr. Carson. &#8220;I
believe the company is well-positioned to successfully execute its role as a full-service provider of home medical equipment and
supplies that places the highest priority on its patients and partners.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>About AdaptHealth Corp</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AdaptHealth Corp. (&#8220;AdaptHealth&#8221;)
is the third largest provider of home medical equipment in the United States. AdaptHealth provides a full suite of medical products
and solutions designed to help patients manage chronic conditions in the home, adapt to life and thrive. Product and services
offerings include sleep therapy equipment (CPAP and BiPAP machines and supplies), respiratory equipment (including oxygen, invasive
and non-invasive ventilation), mobility equipment, wheelchairs, walkers, and hospital beds. AdaptHealth also provides custom bracing
services, hospice focused HME services, wound therapy and nutritional HME services. The company is proud to partner with an extensive
and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing
facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid and commercial insurance payors. As of September
30, 2019, AdaptHealth services over one million patients annually in 49 states through its network of 189 locations. Learn more
at <U>www.adapthealth.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Forward-Looking Statements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release includes certain statements
that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States
Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as &#8220;believe,&#8221;
 &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
 &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221;
 &#8220;seem,&#8221; &#8220;seek,&#8221; &#8220;future,&#8221; &#8220;outlook,&#8221; and similar expressions that predict or indicate
future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not
limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and
projections of market opportunity and expectations. These statements are based on various assumptions and on the current expectations
of AdaptHealth Corp. management and are not predictions of actual performance. These forward-looking statements are provided for
illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as, a guarantee, an assurance,
a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict
and will differ from assumptions. Many actual events and circumstances are beyond the control of AdaptHealth Corp. These forward-looking
statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings
to which AdaptHealth Corp. may become a party or governmental investigations to which AdaptHealth Corp. may become subject that
could interrupt or limit AdaptHealth Corp.&#8217;s operations, result in adverse judgments, settlements or fines and create negative
publicity; changes in AdaptHealth Corp.&#8217;s clients&#8217; preferences, prospects and the competitive conditions prevailing
in the healthcare sector. A further description of such risks and uncertainties can be found in AdaptHealth Corp.&#8217;s filings
with the Securities and Exchange Commission. If the risks materialize or assumptions prove incorrect, actual results could differ
materially from the results implied by these forward-looking statements. There may be additional risks that AdaptHealth Corp. presently
knows or that AdaptHealth Corp. currently believes are immaterial that could also cause actual results to differ from those contained
in the forward-looking statements. In addition, forward-looking statements reflect AdaptHealth Corp.&#8217;s expectations, plans
or forecasts of future events and views as of the date of this press release. AdaptHealth anticipates that subsequent events and
developments will cause AdaptHealth Corp.&#8217;s assessments to change. However, while AdaptHealth Corp. may elect to update these
forward-looking statements at some point in the future, AdaptHealth Corp. specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing AdaptHealth Corp.&#8217;s assessments as of any date subsequent
to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AdaptHealth Corp.</B></FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Equity Group Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brittany Lett</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devin Sullivan</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Marketing</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Vice President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(909) 915-4983</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212) 836-9608</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>blett@adapthealth.com </U></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>dsullivan@equityny.com</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kalle Ahl, CFA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(212) 836-9614</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>kahl@equityny.com</U></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm201313d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm201313d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  R 3<# 2(  A$! Q$!_\0
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MU_#^N,RQC!+!<G W KD\]-P&0<9!&01R"1S2^8F =P()(&.<D#)QCKBOX?\
MP=_P=T>)X]3,7Q(_9'T:ST9;N-;B7P1X^N;O5!!B::XE2+7H+6")O)MYWB68
M(6V!$5F**W]-W_!/S_@I-^S]_P %'/AYJ7CGX*:K=V>I^')[2P\=_#WQ$4M_
M$WA*]O+7S[42KY=N-0M99$GMH]6TO[7I4\]O,D-R9(G4=.-R+-,NI/$XJC'Z
MNF^:5-J;C;2S:;2=[K;>+O:Z,,%G>7YA5^KX:I)5FFXQJ*RDM6FE9-IJS^:L
M?H@T\*@%I47<VQ0S %GZ;%4X9GSQM +9XQFG"1&4,"<'CE'4CZAE!'X@5^6?
M_!1G_@JQ^SK_ ,$VO">D:E\4]1O_ !'\0/%T,\O@;X4>%6M;KQ=K B9X8]0U
M:"=F71_#TUVHM8M4NGMA<7"2V=NSWBO&G\ZFG_\ !W+X@;QFD6L_LBZ)%X-D
MNHEG&F^/KF3QI#IID^:X2RFB_L]7$)W!I'6"1@?*>1""3+\CS7,:/ML/@:R@
M]83G:,91?PRC=*ZE%J5[^E[W'CLZRS+ZBIU\;0<MIQ@^:49+22=FTFI)IK6S
M5F]#[=_X+S_\%;?VI/\ @G5\=?@7X!^ UYX6AT#XB?#;5/%FN)K^B:-J]P;R
MW\97FDM):&]TJZ,(2TBB"*9<R$LV&E>4G[:_X(1?MV_&G_@H7^R9\1/C3\>9
MM+D\5^'/VC/%7PSTY-%TRTTJV70-%^%GP@UZV%Q;6D<$ N#J7C74VN&AAB#3
MR,X4QA=O\A'_  7R_;K^"7_!0GQA^R=\;/@IJ.H_V?'\'_$7ASQAX3UQ$CUS
MP3K]EXY-_=:1J$:Q13_:X+?4+:[6X@B>VO=,FBUBSEGTN1;QOZ)/^#3@"+_@
MG=\94;ED_;0^(1P279E_X4K^S>X*CEI"5BDSMW-QA@&90?J\WR6EE_"&$Q=6
M@J>/JU?95>6$.91BZD7JHR?-=+7G<7II9V/G,LS*IBN)<13C6;PE*DJM)IM-
M\Z4X\UW:W+):**:T/ZD(W0(J[E!50I4$G!5>0,C<0,=<9]:7SH^.6YYR(Y"O
MXL%VCZ$@U^ ?_!1+_@X*_93_ &%?'.M_!S0=+U/X\_&C0)5MO$GA'P7?6,>D
M^#[YXH;DVGB;6KH0V5OJ,,%Q:W5UI4%Y)J%M:75I=2VJ075O+)^-X_X.Y_B.
MWB(6T?['W@\Z MPP=)/'6NP>(OLK3/' _P!C>T^Q1.Z*"3/*D:L<[]A5F^8P
M?#>>8S"?7:.!J+#0BKNI95))17O16EU)6DFD[I^9[^)XARC#U&IXRFXIM3Y6
MY.,E)J2;6FDE)==5]_\ <:)8ST<$[0V!R=K<AL#G!['&#2+-&WW6SP3G#8P,
M#KC'<8YY'(R.:_ /_@G!_P ' '[,G[?7CS2_@UJ.AZY\$_C1K.]=!\*>,YK:
M70?$MU;VT5W+8Z#KUD)88]7E1\6>C:U<65]>3_Z';0/?J]K7HO\ P5#_ ."T
MOPV_X)?^/_A7X$\??!?Q]\3KKXH>#]=\9V%YX.U?PYIHT]=&U>+18K.[36=0
MM5>6666+S3&?)#-E044N.6>59A#%0P<J+C7J6<(-:M22:]79I/SOHE:^T,ZR
MV>'EB8UFZ2^TG&UMT_FFG_GT_;<SQ $[NF> K%CM;:2JA=S 'J5!'(.<$$@F
MC.[#$E0"P"N2 QP#C;D\^@..^*_EA\2_\'2G[+6E? #1OBGI?PH\?WWQ.\4^
M)_%VEZ)\&I;S2)-4T;1/#6FZ?$GC'Q/KMG(VC66FZMJ^HQBTT=;S^V;FTEEN
M[6VN+6SN+N+Y*^%7_!VS%=>,+33_ (R_LI+HO@RZU2"Q&K>!/$T^N:]86=S+
M^]U:\TW53:0RVEK$YDFMM.>[:,*849]JD]U'A;B"K2G76 FJ=.4HN+TJ/EDX
MMQB]6GRW5H[-'(^)\DC4CAY8ZG[>:3BU_#7,DTI/75)I27,M;[']IQGBC#R,
MQV#=G:CNV5RQ 1%9R<*V %)8\+DD _B+_P %3O\ @M%\._\ @ES\0OA=X#\9
M_ _QG\5;SXI^%/$'C+3+WPMXF\/^'8-'&CZK)I)MKX:E87,TAU!E9Q/M8*6V
MR-D U]J:-^W=\$/B'^QSXU_;1^#7B*U^)_PS\$?"GXD?%)]*T6XM=/UR\G^&
M7A#5O&&L>$=1M+^2UET#Q!!!86MO>Z;J,=N]N+V"Z*R6$JW#_P">C_P69_X*
MB^ /^"H'Q/\ @OXY\"?#CQ=\-+7X;?#S6O!NL:3XPU/0M4GU3^VO$TUW]HMV
MT6[NY;06$Z^2/MB0S2G) .<5T\,</5LRS/V->,J>#C.4,0FU#$1DI24HQYO[
MT9Q7[N25G=NYS9]G"PN!PKH2ISQ>*J*-.5I2P_*W92?+)--Q<&OWG7T1_>[_
M ,$M_P#@I%X2_P""F_P5\<?&[P?\-/$WPNTWP;\6M9^$EUH?B?5M/UNXEO-'
M\(>!O'#:BE[I;"#RYK;QR;?<]O:M%)9K!<)%<M]EBQ/^"T'[17QA_9,_X)T?
M'_\ :"^!'B=?!/Q3\ W7PB/A;Q.=%\+^(1IL?BGXV_#KP;KOFZ/XJT#Q!I%\
M)?#OB#6[>..YLI DM^LB,#'E/XZ/^".7_!;_ .&7_!,[]F_XA_!3Q]\%OB'\
M2M8\6_&G7_BI8:MX7U3P[I.EV5EK?@?X>>';C2+R/5[ZUN)B]QX.:=KKRVCB
MCDFCN7C='4?T^?\ !>_QA;_$#_@A[\>_'MI:7%A:>./"O[,'B^TL;K8;FSM_
M$WQX^">LP6ESY9,?GV\=XL,Q0E/,1MI(P3MB\D66<58'"3@JN$Q&+5-*JXSF
MZ*G9?#97::C+FCK:7NV:;YZ.;3QW#N*K*3A7HJI3DX\RCSTYR@^5MMVYH2<?
M>VY=;W9]Z_\ !,+XS?$O]HC]@+]EWXU?&+Q#_P )?\1_B3\,]/\ $7C+7QH^
MCZ -6U2YU"YAFO#I?A^TT[1K E('F>TTBPLM.C8O!8VD%LMO"/OP3)M4L220
M,E8Y2N<<\[#@9SC=CCK7\T'[''_!43]D+_@GU_P2E_8:7]H7XE1:9XIU3X%:
M3>Z)X!\.Z5)J_B[4;636-:B@G.E6"7MU%;R,@_T^ZBMH&#+<.5@D21O4/@M_
MP<G?\$Z/BKXTT[P+KOB/QM\)M0UB>&RT_4OB'X7O+#0$N;F4P6@U/4;>![32
MEN'!DADU*>TBG@_TB!FM\2'QZ^49I4Q6-JT,!46"I8O%PBK?O>2&*Q4(."T7
M*X0@XI0VL>O0S? 0I87#U<;1^M3P^';:O[-2="@VI.[U4FU*\E[RD?T)AU;D
M'/X$>_<4!E.3GIUX([X[C\O7J.*Q=%UK2M9T?3]8TS4K+4]-U*RLKVRU+3W6
M73[ZTO[2WO;2]LY8FEB>SN[:Y@N;>9))86@GA=975U9ORW_;:_X+)?L2?L(:
M]-X(^+'Q"?7/B;&J37'PY\":9<>(_$^F6T[D6YUV/3$O(-"F>/9<"#69K"=K
M21+\V\=I)'*WG4:&(Q,I*C3DE!M3YXOFBXS<)7UBE:49)WV:L=]7$TL/2YZL
MXN32<>3:2:332;;LTTT^S3/UBWJ?7_OEOSZ=/?I[TNX8SV]<'_"OP ^!7_!Q
MG_P3X^,7CW3?AOKVO^-?@SK^NSVUIHMW\4O#%SI.E7]U?WIL+*QDU."&2QL)
M;JY^2!=0GM7DA9;H9MG6=OWGTW5]/U*QLKZQN[2]L;VTMKNQNK26&YM+NTNK
M<7-K<6=Q;/+;W,$]MBXADMY98I;?$T3O"5>GC<+B\MG"&,I.]1*<94TG#DFE
M*#;C*HOAE%OWKIWO&+T2H8RCB9<E.24[)J,MW=+9:-[[?BS6$B$,?FPI(.4<
M<CC(RH+#CAERIZ@FD$J$9!X_W6^N ,9)]ASVZU\'_MI_\%$_V5OV!O"UMXK_
M &B_B7IWAF?6(KJ7PQX-L;2;6O&GBA;1U2>XT30-,6^U2ZL(I76.74%L18PN
MLJS7$9@G$?Y*I_P=!_L%P-9RZYX.^.FAZ)<7D$$GB34? TO]FV=K=.%M-122
M.%WN8+J)DN+;R%D>:%U=%96R>K#97F.+PTL92P=;ZO!M-R24FD[<T=5>+M=-
M1E=-,QQ&:8'#U.6IBZ/*M)I-N49)VE%O9---/31KK8_I8\Q2-RCCGD@@Y')X
M8 Y'H1D>W0_S9?M@_P#!0O\ :L^%/_!<O]D3]BGP5XYMM+_9[^,/A3X;:OXO
M\*2>%/ =[<ZG)XDUOXEZ9J<]OXBU?PGJ?BBP$A\)PQ^7I^N6#*8R8PD;AF_;
MW]F;]JGX'_M=?"[3/BW\!/'ND^//!>HW,MHU]8F2&]TS4(C$MQH_B#3KB*"[
MT;7;:258+G3;R"&0W$<ZVHGBB=A_+I_P425T_P"#G'_@G-,HW_\ %L_@_P"7
M'E4)%OXT_:"N)B=Y4 I$&<*Q#.<1H&<[:[>&\%]<S/&X+$4[>PR/,,PIJ<??
M]O0C4E3C+FT<$XQNE%-])69PYQBE3PF$Q4*K=*O6C%N#_P"74M5*/9VLW>_H
MMC^F/]K/]LOX&?L._#7P]\4OVA?$LG@[P1XA\::9\/\ 3=2CTN[U(2>*=5T7
M7_$%EI[?9!=3M+/H_A?7;Y;N6!+8_8##/-#=W-I;W'T9X(\:Z)\0?!7A/Q[X
M9NI;[PWXY\-:'XN\-7SPM&]YH7B+2[76=)NY44%;=KFPO+>8HY !?:I(Q7\1
M7_!Q9_P5)_90_:R_9]TG]E;X,^)/%^L_&#X*?M>V^J>.],U/X?>)]#T6TL/A
MCX(^.7@?Q=+8:G>SV*7TEAXDU2PLK<(BWVIQ7!U*PL);&UO9;3]MO^"8?_!8
M7]B3]H'2OV8?V,OAKXL\<7?QSMO@AX4\.7FDZA\//$NB:1'K'PK^&<+>+K1?
M$E_8BS=;./PMK+6]S?75O+?BWB6V,MS?6\$KQ&18RAD6$S:I%JKBJU2,HI)4
MHP483A-1YG.,9^T:@Y3;=M8QW;PN;TZN8UL#I[*CAZ,X3L_:2<J</B?P];M*
M"UZGAO\ P3!_X*"_M7?M&_\ !5[_ (*0_LS_ !B^)Z>+?@O\ /%_Q]L/A/X+
M;P5\/- C\.6'@;]I3_A O"UO+XAT+PEI7BO7/L'A:XMK)+K7=4U-[B1([N[O
M+V\5IS_2ZH&TJ-Q&  2I&<=^%"_D #VP.G\/W_!+GXW_  U_9]_X+3_\%H?B
ME\7?%FC?#_P!X:\3_M7ZEKGB#Q!<K:0F9_VQM*\FSLFO5ADN;B4R^5!:VT,E
MPS.J^2K A?T:\0?\'1/[$NFZT!H'PW^-WBSP*M_<61^(]EX0GM-!E2VF>+[5
M9QZG#97URLB()Q!':-=1(ZK/#'(&0=6<9/B9XW"_5,!4IIX/ 2TBH1E.>#P\
MZDD^6*ESSDYZ-M<R4G=V.3*<SPM+!XMXK,(5$L3BK)MN48_6*ZC'=VY5:-M/
MATT1_30)HAA3(@8#!4L,@CKQUXHKXB_8K_;Z_9O_ &]_AW<_$;]G[QJ/$EAI
M-Q;VGB?P_?V-U8>*/#%[?132V<&KZ)=6MMJ%NLWV:[CM[K[,]E=&WG-K<S)%
MYCE?/5,+B:,YTZT5"I&4DXN,DUJ[?:U]5H];'MT\;3JPC.DXRIRBN63>ZLM=
M.Z:?S/L^6YCB=5)8EI90"L<C@/NP%+(C*I'^T1@G)(%?SR?M.?%_XJZ+\>?B
MSIND^/?$NGZ=IOB9H;*QMM1E2&UAMK2TO(X;6)6&Z(O,T86)6"*,-C%<S\>?
MB]\4]-^-WQCTW3?B7X_L;#3_ (J?$.QL;&S\8>([6SLK.U\7:O;VUI:VT-\D
M%O;6T$:0P00HL442)'&JHJ@?,^J:IJ&M7UWJ>L7][J6I7T@FU"_U2ZDNM3O)
M[M%LVG:[N'>:60I"LGG7+F64GS&9G8D_J.0<(1PDZM;$X_+Z\5@Z.*A"3YVO
M;TJ6(4)I25G%5E"25G>+VU1_ GC3XZU.*:.!R#),EXHX<QW#O$6/AFV-K)T,
M/B<-@,?CL"YX.:I1<XUU@_K%-RE-<E:"Y9+5_P!4?@F]DN/ 7ABZO;GSKF?P
MGHEQ<W%R_G32W/\ 944UQ<R;<F25S,LLA^\S,<9.0/R"\>?LD_&JVU#Q9XLN
MM'TS^Q+.\\1Z[/,NL:2MXED+F]OGNMIU0,P^SJ\AMU0SC'E^5O(6OA>V^,OQ
M:MA965I\3_B!!:)*EM!:1^*]?MX8('6UM4LUACU".&WBA:,VZQHJ01J@"!8M
MF?Z/M&TZ^\9?!73]+DNWGO?$GP[BL'U"^E>[GEN=7\-/$-0N;F1Y)+F2:XNA
M//*[R/(SO(S,69J_E/Z17T?LA\1LM<L\J8^I_J_2S?%\.8+*,?++\%/'9M@Z
MZK5<53H)UJKC&O:BH5J=II.?,G)/^H_ [QHP7B%2G@<+DF:Y94RK X/#RQ.<
MPGRXNIA\+A<+/$*7)2YHUYX>6(33]Z-:ZW5OPJ^'?P^\4?$KQ!I_A+PI!:ZC
MKDUI>7J":YMK8BUM45IRUS<3V]LAB$BYB>=9220B,0<?JA^QS\#OB%\'I?B$
M_C;3K2T'B!?"PTCR+^QO23ID.LI>G%K>79A*-=P.5F\HNSC87V/MI? 3]DSQ
M#\(/B%;^,K[Q1I>K65MI&KZ>+*SM)8)GFO((8XIS+*B*6D=#(_.%8\CD5]]1
MQY7([]">X)ZGZCD\<D\]*_FGZ,_T:\-PCA\'QEQ5',Z?$N5YOF-3*L-#'U88
M"6'Y)Y9AGB,-*]:JU@L/A9RDJT7/$.I-WC+D7] YACW4BHQC1;Y8J3C&7*Y6
MCS<OO/W6TW%.[46DWO?\A?\ @LO^S)^TM^V5^QSJ7[._[,NL^&= \1^-_B7X
M0_X3N7Q5KUYX5M+OX;Z!!KOB75+*'4+17CNDU?Q?:?#W3[B)R(;BUO-8LICY
MEPL"_P __P#P3F_X-XU_9[^/&J?$S_@I9=_!KQ%\*/!7@>^N?!WA0^-[<6.J
M>-Y]3TD66M^*+*ZN+*)M)TO0D\4VMC8_NE@GF\-,JC[,$/Z[_P#!P5_P4?\
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ML!?&[S61,?MA^,N78!2&^"_P,FR')VE?+1PS!L+)'+"Q$T;QK]R_\'$4B_\
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MW*R.VYT=?B!\?H%C9]S!VF@/SLKR '.Y\UXE_P $&_A+\.OV?_\ @N?_ ,%
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MT(4?;/"X3#8651.,8RM4EAI5%S-O]XN9MW;A6(;1N7D 8'R]AZX//O3MK '
M_AP!D>V!^7TJ6BN9THOV5FXQI3<XPC90;?,_>2CJKR;LK:GJQ7*K:M))+FUL
MDDM/N5S^;/\ X.2?V!_BI^V/^R_\//B!\%?"[^,?B1^S;XK\2:^_AG3HX9/$
M6L?#[Q[I.GZ=XWMO#;7=S;6OVZPO?"O@GQ-+;)*U[>P:%=V>GP7-W<16\O\
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
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
